Imatinib, as the first targeted drug capable of inhibiting BCR-ABL kinase activity for the treatment of CML, is still resistant to imatinib in some CML patients (Druker et al., 2006). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.